Journal article
Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
Abstract
e19062
Background: AZA is a standard of care for patients who have HR-MDS. Given the limited availability of large datasets describing outcomes in the current treatment paradigm of HR-MDS, this analysis aimed to aggregate clinical outcomes associated with AZA monotherapy for treatment-naïve HR-MDS. Methods: CENTRAL, EMBASE, and MEDLINE were searched to identify interventional, prospective, and retrospective observational …
Authors
Hasegawa K; Wei AH; Garcia-Manero G; Daver NG; Rajakumaraswamy N; Iqbal S; Chan RJ; Hu H; Tse P; Yan J
Journal
Journal of Clinical Oncology, Vol. 40, No. 16_suppl, pp. e19062–e19062
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.e19062
ISSN
0732-183X